NeuroSense Amends $150M Shelf as ATM Capacity Shrinks to $3.8M and Nasdaq Delisting Risks Mount
NRSN is trading near its 52-week low of $0.46 (3.5% above the low).
Summary
NeuroSense's shelf registration amendment reveals a dwindling ATM facility with just $3.8M remaining and explicitly warns of Nasdaq delisting risks from non-compliance with bid price and market value rules, with a September 29 deadline to cure.
Key Events · Financing and Capital Events · NRSN
-
ATM Capacity Reduced to $3.8M
The ATM prospectus supplement now reflects only $3,789,822 in remaining capacity, down from the original $6.5 million, after selling 6,762,825 shares under the Sales Agreement to date, including 2,690,196 shares in 2026.
-
Nasdaq Delisting Risk Disclosed
The filing discloses non-compliance with Nasdaq's $1.00 minimum bid price and $35 million MVLS rules, with a September 29, 2026 deadline to regain compliance. It also warns of the new $5 million minimum MVLS rule effective July 22, 2026, which could trigger immediate delisting.
-
Going Concern and Cash Runway Pressure
The company's auditor report includes a going concern paragraph, and the filing notes limited cash resources, cost-reduction measures including workforce reductions, and the need for additional financing to support operations.
-
Dilution from ATM Sales
Assuming sale of the full $3.8 million ATM at $0.4802 per share, approximately 7.9 million new shares would be issued, representing about 21% of the current outstanding shares, causing immediate dilution of $0.38 per share to new investors.
Analysis · NRSN · Life Sciences
An amendment to NeuroSense's $150 million universal shelf registration updates the at-the-market (ATM) prospectus supplement, revealing that heavy usage has cut the remaining ATM capacity to $3.8 million from the original $6.5 million. To date, 6.76 million shares have been sold under the Sales Agreement, including 2.69 million in 2026. More critically, the filing explicitly discloses non-compliance with Nasdaq's $1.00 minimum bid price and $35 million market value of listed securities rules, setting a September 29, 2026 deadline to regain compliance. It also highlights a new $5 million minimum MVLS rule effective July 22, 2026, which could trigger immediate delisting if the company's market value falls below that threshold. With a market cap of only $16.8 million and shares trading at $0.48 near the 52-week low, the ATM overhang and delisting risk pose material threats to the company's capital-raising ability and listing status.
At the time of this filing, NRSN was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.8M. The 52-week trading range was $0.46 to $1.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.